An open-label trial of risperidone in children with autism

Diler, Rasim Somer; Fırat, Sunay; Avcı, Ayşe

doi:10.1016/s0011-393x(02)80009-1

Cited by 25 publications

(17 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar increases are reported in non‐Medicaid data . These increases were probably associated with the results of short‐term clinical trials, which found that second‐generation antipsychotic medications were effective in the treatment of irritability and impulsivity in the context of autism spectrum disorders, bipolar disorder, and disruptive behavior disorders . In addition, blinded discontinuation of risperidone among children 5–17 years old who were treated for disruptive behavior disorders and irritability, and aggression among children with pervasive developmental disorder (PDD) was reported to be associated with a rapid return of disruptive and aggressive behaviors after 6 months compared with children who remained on risperidone treatment.…”

Section: Introductionsupporting

confidence: 56%

“…In addition, blinded discontinuation of risperidone among children 5–17 years old who were treated for disruptive behavior disorders and irritability, and aggression among children with pervasive developmental disorder (PDD) was reported to be associated with a rapid return of disruptive and aggressive behaviors after 6 months compared with children who remained on risperidone treatment. Antipsychotic medications were generally well tolerated in these studies, with sedation, weight gain, and elevated prolactin levels as the primary issues . Aripiprazole and risperidone are indicated for the treatment of irritability in the context of autism for children 5–17 years old with irritability.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Exposure to antipsychotic medications over a 4‐year period among children who initiated antipsychotic treatment before their sixth birthday

Constantine

Jentz

Bengtson

et al. 2011

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

show abstract

Section: Introductionsupporting

confidence: 56%

Section: Introductionmentioning

confidence: 99%

Exposure to antipsychotic medications over a 4‐year period among children who initiated antipsychotic treatment before their sixth birthday

Constantine

Jentz

Bengtson

et al. 2011

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

show abstract

“…Four controlled trials were excluded, three because not all participants were diagnosed with a PDD Hellings et al, publish forthcoming;Aman et al, 2002), and one because it did not include the effects on behavioural problems among the outcomes . Eighteen trials were excluded because they lacked a control group (Perry et al, 1997;Horrigan et al, 1997;Nicolson et al, 1998;Cohen et al, 1998;Masi et al, 2001;Masi, Cosenza et al, 2001;Vercellino et al, 2001;Malone et al, 2002;Diler et al, 2002;Potenza et al, 1999;Koshes et al, 1997;Fatemi et al, 1998;DeLong et al, 1998;Peral et al, 1999;Pertejo et al, 2000;DeLong et al, 2002;Martin et al, 2003;Hollander et al, 2000). Nine case reports/case series/case analyses and two retrospective chart reviews were also excluded (Schreier, 1998;Posey, Litwiller et al, 1999;Dartnall et al, 1999;Hughes et al, 2002;Simeon and Milin, 2002;McDougle et al, 2002;Stavrakaki et al, 2004;Steingard et al, 1997;Posey, Walsh et al, 1999;Sokolski et al, 2004;Namerow et al, 2003).…”

Section: Search Resultsmentioning

confidence: 99%

Systematic review of randomized controlled trials of atypical antipsychotics and selective serotonin reuptake inhibitors for behavioural problems associated with pervasive developmental disorders

2005

View full text Add to dashboard Cite

A systematic review of randomized controlled trials of the use of atypical antipsychotics and selective serotonin reuptake inhibitors in the treatment of behavioural problems associated with pervasive developmental disorders is reported. A search through both published and unpublished literature, including contacting drug companies and known experts in the field was undertaken. Six trials met the criteria for inclusion in the review. They largely suffer from methodological weaknesses; only two trials had satisfactory methodological quality. The heterogeneity in outcome measurements prevented from conducting a meta-analysis. There is yet no coherent body of data concerning the effects of these medications across all sub-classifications of pervasive developmental disorders, across all age categories, and concerning their medium- and long-term effects, and their effects on quality of life. Atypical antipsychotics and selective serotonin reuptake inhibitors may be of benefit for behavioural problems associated with pervasive developmental disorders. Risperidone has been the best studied among these medications. Atypical antipsychotics appear to have a low risk of extrapyramidal symptoms during short-term treatment. The reviewed trials cannot provide data on the use of selective serotonin reuptake inhibitors in the treatment of children with pervasive developmental disorders. No firm conclusions for clinical practice can be drawn. Larger, well-conducted randomized controlled trials with long-term follow-up are needed.

show abstract

“…Aside from changes in synaptic dopamine uptake and degradation, changes dopamine receptor function and avidity have been reported [59][60][61], as have changes in dopamine synthesis and DOPA decarboxylase. Additionally, it has been observed that pharmacologic manipulation of dopamine has clinical efficacy in ASD [62,63], for example with risperidone, a drug approved to treat ASD.…”

Section: Adrenergic Cns Changes In Autismmentioning

confidence: 99%

L1-79 and the Role of Catecholamines in Autism

Rothman¹

2021

Autism Spectrum Disorder - Profile, Heterogeneity, Neurobiology and Intervention

View full text Add to dashboard Cite

A growing body of evidence supports a role for catecholaminergic dysfunction in the core symptoms of autism spectrum disorder (ASD). This paper reviews the direct and indirect role of catecholamines on the central and peripheral nervous systems in ASD. Catecholamines innervate every tissue in the body and almost all tracts of the brain, providing a common neurologic regulatory mechanism for all ASD symptoms. Because the morphology of the catecholaminergic synapse is regulated by growth factors that are released contemporaneously with neurotransmitters, an event that results in abnormally large catecholamine release, will also release high levels of growth factors, which can result in the budding and arborization of nerve terminals. Here, we hypothesize that a hypertrophic synaptic morphology can occur in catecholaminergic systems and increase catecholaminergic tone throughout the body, resulting in an imbalance between catecholaminergic neurologic mechanisms and those that oppose them, and consequently pathology. By exerting a presynaptic effect to inhibit tyrosine hydroxylase and thus the synthesis, storage and release of all catecholamines, L1–79 (a tyrosine hydroxylase inhibitor) may diminish neurotransmitter release and its associated growth factors exerting a therapeutic effect on ASD by reducing the hypertrophic morphology of the synapse and bringing catecholamines back into a homeostatic balance with oppositional neurologic and metabolic influences.

show abstract

An open-label trial of risperidone in children with autism

Cited by 25 publications

References 15 publications

Exposure to antipsychotic medications over a 4‐year period among children who initiated antipsychotic treatment before their sixth birthday

Exposure to antipsychotic medications over a 4‐year period among children who initiated antipsychotic treatment before their sixth birthday

Systematic review of randomized controlled trials of atypical antipsychotics and selective serotonin reuptake inhibitors for behavioural problems associated with pervasive developmental disorders

L1-79 and the Role of Catecholamines in Autism

Contact Info

Product

Resources

About